Anagliptin vs Gosogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Gosogliptin

Marketed by SatRx under a licence from Pfizer

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT03088670 · Phase 3 · completed

This open-label trial randomly assigned 299 people with newly diagnosed type 2 diabetes to gosogliptin or vildagliptin. The primary measure was the change in HbA1c at weeks 12 and 36. The published preliminary report shows that HbA1c fell in both groups by week 12 with no significant difference between them, but it does not report a formal test of whether gosogliptin was not worse than vildagliptin, and it does not report week 36. Thus it is not possible to say whether the primary comparison was met. The figures come from the peer-reviewed report in the journal Diabetes Mellitus.

Reported efficacy

Mean change of HbA1c (at Weeks 12 and 36 from baseline): Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53). (unclear)

Result source: NCT03088670

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinGosogliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
—Not posted · NCT03088670
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT03088670
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT03088670
Fasting plasma glucose, change—Not posted · NCT01529528—Not posted · NCT03088670
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT03088670

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Gosogliptin
—Not posted · NCT03088670

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Gosogliptin
—Not posted · NCT03088670

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Gosogliptin
—Not posted · NCT03088670

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Gosogliptin
—Not posted · NCT03088670

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Gosogliptin
—Not posted · NCT03088670
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Anagliptin

HbA1c -0.51% vs 0.23% placebo @ 24wkanagliptin 200 mg
absolute change · percentage points
NCT01529528 · Phase 3 · sponsor-reported, not registry data
show 2 more results
-0.5% vs 0.23% placebo @ 24wkanagliptin 100 mg
NCT01529528 · Phase 3 · sponsor-reported, not registry data
-0.85% vs -0.83% sitagliptin @ 24wk
NCT01529541 · Phase 3 · sponsor-reported, not registry data

Gosogliptin

HbA1c 7.41% vs 7.34% vildagliptin monotherapy @ 12wk
absolute value · percentage points
NCT03088670 · Phase 3 · sponsor-reported, not registry data
HbA1c 7 0 or Less 41% vs 44% vildagliptin monotherapy @ 12wk
responder rate · % of participants
NCT03088670 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Gosogliptin's landscape